A gauge invariant study of the monopole condensation in non Abelian lattice gauge theories

We investigate the Abelian monopole condensation in finite temperature SU(2) and SU(3) pure lattice gauge theories. To this end we introduce a gauge invariant disorder parameter built up in terms of the lattice Schr\"odinger functional. Our numerical results show that the disorder parameter is different from zero and Abelian monopole condense in the confined phase. On the other hand our numerical data suggest that the disorder parameter tends to zero, in the thermodynamic limit, when the gauge coupling constant approaches the critical deconfinement value. In the case of SU(3) we also compare the different kinds of Abelian monopoles which can be defined according to the choice of the Abelian subgroups.Comment: 18 pages, 7 figures, LaTe

Matter degrees of freedom and string breaking in Abelian projected quenched SU(2) QCD

In the Abelian projection the Yang--Mills theory contains Abelian gauge fields (diagonal degrees of freedom) and the Abelian matter fields (off-diagonal degrees) described by a complicated action. The matter fields are essential for the breaking of the adjoint string. We obtain numerically the effective action of the Abelian gauge and the Abelian matter fields in quenched SU(2) QCD and show that the Abelian matter fields provide an essential contribution to the total action even in the infrared region. We also observe the breaking of an Abelian analog of the adjoint string using Abelian operators. We show that the adjoint string tension is dominated by the Abelian and the monopole contributions similarly to the case of the fundamental particles. We conclude that the adjoint string breaking can successfully be described in the Abelian projection formalism.Comment: 16 pages, 10 figures, 2 table

Evolution of late steps in exocytosis:conservation and specialization of the exocyst complex

Background: The eukaryotic endomembrane system most likely arose via paralogous expansions of genes encoding proteins that specify organelle identity, coat complexes and govern fusion specificity. While the majority of these gene families were established by the time of the last eukaryotic common ancestor (LECA), subsequent evolutionary events has moulded these systems, likely reflecting adaptations retained for increased fitness. As well as sequence evolution, these adaptations include loss of otherwise canonical components, the emergence of lineage-specific proteins and paralog expansion. The exocyst complex is involved in late exocytosis and additional trafficking pathways and a member of the complexes associated with tethering containing helical rods (CATCHR) tethering complex family. CATCHR includes the conserved oligomeric Golgi (COG) complex, homotypic fusion and vacuole protein sorting (HOPS)/class C core vacuole/endosome tethering (CORVET) complexes and several others. The exocyst is integrated into a complex GTPase signalling network in animals, fungi and other lineages. Prompted by discovery of Exo99, a non-canonical subunit in the excavate protist Trypanosoma brucei, and availability of significantly increased genome sequence data, we re-examined evolution of the exocyst. Methods: We examined the evolution of exocyst components by comparative genomics, phylogenetics and structure prediction. Results: The exocyst composition is highly conserved, but with substantial losses of subunits in the Apicomplexa and expansions in Streptophyta plants, Metazoa and land plants, where for the latter, massive paralog expansion of Exo70 represents an extreme and unique example. Significantly, few taxa retain a partial complex, suggesting that, in general, all subunits are probably required for functionality. Further, the ninth exocyst subunit, Exo99, is specific to the Euglenozoa with a distinct architecture compared to the other subunits and which possibly represents a coat system. Conclusions: These data reveal a remarkable degree of evolutionary flexibility within the exocyst complex, suggesting significant diversity in exocytosis mechanisms. </p

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Zoosporic marine fungi from the Pacific Northwest (U.S.A.)

An investigation of the zoosporic fungi in the vicinity of the Friday Harbor Laboratory, San Juan Is., Washington, revealed the presence of great numbers of fungi. With one exception ( Olpidium sp. ) these were all biflagellate organisms. Predominating were species (11) of Thraustochytriaceae which abounded in water, in association with seaweeds, intertidal sands, and particularly on the surface of bottom samples down to depths of 298 m. A twelfth species of this group has several peculiarities and needs further investigation. Of the algal parasites, one on Polysiphonia and Pterosiphonia is considered new and termed Eurychasma joycei n. sp.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46146/1/203_2004_Article_BF00410220.pd

Invasão biológica por porcos selvagens (Sus scrofa linnaeus, 1758) em uma área protegida da Mata Atlântica

This is the first record of the biological invasion by wild pigs (Sus scrofa Linnaeus, 1758) in the Mata dos Godoy State Park (PEMG), an important protected area in the State of Paraná, Brazil. The PEMG landscape is identified as a priority for the conservation of the Atlantic Forest by sustaining a high richness of native species. Using camera traps, we report 21 records of wild pigs with groups of up to 26 individuals within the limits of this park. We highlight the need for quick action to contain the invasion, and thus reduce the potential negative effect on the region's natural and agricultural ecosystems. Early detection of biological invasion events is essential to guide managers to use suitable management practices and thus avoid damage to both biodiversity and local economies.Este é o primeiro registro da invasão biológica por porcos selvagens (Sus scrofa Linnaeus, 1758) no Parque Estadual Mata dos Godoy (PEMG), uma importante área protegida do Estado do Paraná, no Brasil. A paisagem do PEMG é apontada como prioritária para a conservação da Mata Atlântica ao sustentar uma alta riqueza de espécies nativas. Através de armadilhas fotográficas, reportamos 21 registros de porcos selvagens com grupos de até 26 indivíduos dentro dos limites deste parque. Evidenciamos a necessidade de ações rápidas para conter a invasão e assim reduzir o potencial efeito negativo sobre os ecossistemas naturais e agrícolas da região. A detecção rápida dos eventos de invasão biológica é imprescindível para orientar os gestores no uso de práticas de manejo apropriadas e assim evitar prejuízos tanto para a biodiversidade como também para as economias locais

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)